Saredutant

drugbox
IUPAC_name = N- [(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl] -N-methylbenzamide

---

width = 300
CAS_number = 142001-63-6
ATC_prefix =
ATC_suffix =
PubChem = 104974
DrugBank =
C = 31 | H = 35 | Cl = 2 | N = 3 | O = 2
molecular_weight = 552.5345 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Saredutant, or SR 48968, is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by sanofi-aventis. Its mechanism of action is different from antidepressants currently available on the market. It works by blocking the effects of Neurokinin A at the NK-2 receptor.

Phase III studies are currently being conducted.